CCCC vs KEYS · rev $35.6M vs P/E 57, rev $4.98B
C4 Therapeutics Inc (CCCC) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
CCCC currently screens at market cap $425.7M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the CCCC and KEYS stock pages for the full models.
Not investment advice.